UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss including noncontrolling interests in subsidiaries	$ (73,266)	$ (163,565)
Adjustments to reconcile net loss including noncontrolling interests in subsidiaries to net cash used in operating activities:
Change in fair value of investment, net	0	2,752
Gain on sale of investment	0	(3,591)
Depreciation and amortization	3,369	1,897
Amortization of debt discount and issuance costs	51	549
Change in fair value of Series A redeemable convertible preferred stock embedded derivatives	(3,942)	13,691
Change in fair value of Series A warrants	(896)	11,603
Change in fair value of Series B warrants	(23,260)	173,615
Compensation expense for share-based awards	1,174	450
Loss on foreign currency exchange	813	24
Change in fair value of equity securities	172,203	(37,849)
Gain on sale of equity securities	(66,876)	(819)
Earnings on equity investment in joint venture	0	(2,730)
Deferred income taxes	(15,039)	0
Changes in assets and liabilities:
Accounts receivable	318	(3,919)
Inventories	(1,084)	0
Prepaid expenses and other assets	(1,246)	(843)
Accounts payable and accrued expenses	4,261	2,332
Royalties and contingent legal fees payable	(161)	283
Deferred revenue	418	0
Net cash used in operating activities	(3,163)	(6,120)
Cash flows from investing activities:
Patent acquisition	0	(11,000)
Sale of investment at fair value	0	3,591
Purchases of equity securities	(92,877)	(9,200)
Sales of equity securities	102,842	2,702
Purchases of property and equipment	(34)	(33)
Net cash provided by (used in) investing activities	9,931	(13,940)
Cash flows from financing activities:
Repurchase of common stock	(10,988)	0
Issuance of Senior Secured Notes, net of lender fee	0	50,000
Paydown of Senior Secured Notes	(15,000)	(50,000)
Dividend on Series A Redeemable Convertible Preferred Stock	(700)	(260)
Taxes paid related to net share settlement of share-based awards	(72)	0
Net cash used in financing activities	(26,760)	(260)
Decrease in cash and cash equivalents and restricted cash	(19,992)	(20,320)
Cash and cash equivalents and restricted cash, beginning	309,361	200,546
Cash and cash equivalents and restricted cash, ending	289,369	180,226
Supplemental schedule of cash flow information:
Income taxes paid	2	10
Noncash investing and financing activities:
Patent acquisition in exchange of notes receivable	0	4,000
Patent acquisition accrued liabilities	$ 0	$ 15,000